Cite

    Kobat, H. et al. (2023). Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?. Journal of oncology pharmacy practice. pp. 646-662. [Online].